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ABSTRACT
Introduction: Responsible conduct of research
implies that results of clinical trials should be
completely and adequately reported. This article
describes the design of a cohort study that aims to
investigate the occurrence and the determinants of
selective reporting in an inception cohort of all clinical
drug trials that were reviewed by the Dutch Institutional
Review Boards (IRBs) in 2007. It also describes the
characteristics of the study cohort.
Methods and analysis: In 2007, Dutch IRBs
reviewed 622 clinical drug trials. For each trial, we
assessed the stages of progress. We discriminated
five intermediate stages and five definite stages.
Intermediate stages of progress are: approved by an
IRB; started inclusion; completed as planned;
terminated early; published as article. The definite
stages of progress are: rejected by an IRB; never
started inclusion; not published as article; completely
reported; selectively reported. We will use univariate
and multivariate Cox regression models to identify
trial characteristics associated with non-publication.
We will identify seven trial-specific discrepancy items,
including the objectives, inclusion and exclusion
criteria, end points, sample size, additional analyses,
type of population analysis and sponsor
acknowledgement. The percentage of trials with
discrepancies between the protocol and the publication
will be scored. We will investigate the association
between trial characteristics and the occurrence of
discrepancies.
Ethics and dissemination: No IRB-approval is
required for this study. Access to confidential research
protocols was provided by the Central Committee on
Research Involving Human Subjects. We plan to finish
data collection in June 2015, and expect to complete
data cleaning, analysis and manuscript preparation
within the next 3 months. Hence, a first draft of an
article containing the results is expected before the
end of October 2015.
INTRODUCTION
Responsible conduct of clinical research
implies that results of clinical trials should be
completely and adequately reported.1 2
However, a significant part of clinical trial
results is never reported: on average, only
50% of clinical trials that are started are pub-
lished in the scientific literature.3–20 As pub-
lished reporting gives the nature or direction
of the trial conclusions, incomplete report-
ing may result in publication bias.8 9 19 21–24
For example, if negative findings are more
often not published than positive findings,
the overall evidence synthesis will be biased,
which can harm patients.25–27
Publishing negative results is sometimes
judged irrelevant or uninteresting by the
investigator, the journal editor or the sponsor
of the trial.28 Negative trials, however, add
valuable information to the body of evidence
on the effects of the interventions studied.
Moreover, publishing negative findings can
Strengths and limitations of this study
▪ The major strength of our study is that we inves-
tigate the occurrence of both the non-publication
rate and selective publication in the same cohort.
By addressing both issues, our analyses will
likely offer more insight than most of the previ-
ous publications on this topic.
▪ We use original protocol data, which enables us
to assess discrepancies more completely and
objectively than if we would have used trial regis-
try data only. We will not have to depend on
voluntary provision of access to the original
protocols in our assessment of selective report-
ing, which is an important limitation of most
other studies.
▪ The most important limitation of our study is
that we have to rely on the response to the ques-
tionnaire of the investigators and sponsors for
verification of whether the study was published.
Hence, non-response may introduce bias in our
study. To assess the potential impact of non-
response bias, we will compare characteristics
between responders and non-responders.
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prevent the start of unnecessary new clinical trials. This
may make the use of resources for investigators and spon-
sors more efficient.29 30
Selective reporting of trial results comes in two forms.
First, selective reporting can mean that the trial at issue
is never published in the scientific literature (non-
publication). This can be judged by searching for publi-
cations on trials included in an inception cohort, for
example, using information from a trial register.6 12 16 31
Second, selective reporting may indicate that a trial is
published in the scientific literature with changes, addi-
tions or omissions of study aspects or findings (selective
publication).32–34 The second form of selective reporting
is more subtle and can only be judged by comparing
published reports to the full original study protocol.
Non-publication rates of 10–88% have been reported
in the literature.3 5 7–12 14–19 Selective publication was
identified by studying discrepancies between the proto-
col and publication in reporting end points, sample size,
statistical methods and subgroup analysis.33 35–37
That non-publication and selective publication can
lead to patient harm was also shown in clinical trials
with drugs intended for marketing authorisation.15 38 39
Some new drugs had to be withdrawn from the market
after additional data was revealed showing harmful
effects. For example, clinical data on the new anti-
inflammatory drug rofecoxib were neither published in
the literature, nor revealed to the regulators.39 Other
examples of non-publication and selective publication
potentially resulting in patient harm include the antihy-
pertensive drug reboxetine,38 and the antiarrhythmic
drug lorcainide.22 The negative media attention about
these and other drug trials has caused a decrease of the
public’s trust in the pharmaceutical industry and
medical research.40 41 This had led to various codes and
guidelines aiming at reducing selective reporting42–44 to
be developed. However, recent research showed that
these guidelines have only reduced selective reporting
marginally.45 46
Most studies that investigate selective reporting use
data from a public registry, like clinicaltrials.gov.
However, not all clinical trials are registered in public
registries, and details of the original trial protocol are
often unclear or lacking because these registers often do
not include full study protocols. Also, information pub-
lished in public registries may be subject to selective
reporting as well. The availability of the full and original
trial protocol submitted to an Institutional Review Board
(IRB) enables the tracking of the stages of progress of a
study from the start. Therefore, to our opinion, starting
with a series of consecutive full trial protocols submitted
to an IRB in a defined time window and in a defined
area is the best approach to examine non-publication
and selective publication. To date, few studies have been
carried out using this approach.47
We report the design of a study that aims to evaluate
reporting practices in an inception cohort of clinical
drug trials in the Netherlands. The primary objective of
the study is to investigate non-publication and selective
publication in an inception cohort of clinical drug trials.
With regard to non-publication, we will identify factors
associated with non-publication. With regard to selective
publication, we will evaluate factors associated with dis-
crepancies between the protocol and the publications of
the trials. The secondary objective of this study is to
investigate whether selective publication is associated
with the direction of trial conclusions. Furthermore, we
describe the characteristics of the study cohort.
METHODS AND ANALYSIS
Characteristics and data sources
We identified all clinical drug trials reviewed by the
Dutch accredited IRBs48 between 1 January 2007 and 31
December 2007 (n=622). These trials define the incep-
tion cohort. According to previous studies, a 7-year time
window is sufficient for most trials to recruit participants,
collect data, prepare a manuscript and publish the
manuscript.5 8 16
Also, we identified the characteristics of these trials
(see online supplementary table S1). The used source
was the General Assessment and Registration (GAR)
form. This is a standard obligatory form that investiga-
tors submit to the IRB. For 194 trials, multiple thera-
peutic areas were indicated. Two investigators (CAvdB
and CTMB) independently examined whether these
trials could be reclassified to a single therapeutic area
and reclassified the combination trials as one thera-
peutic area. Differences were solved by consensus after
involving a third investigator (GHK). To reduce the
large number of different therapeutic areas, we reclassi-
fied the variable to the International Classification of
Diseases, V.10.49 This reclassification retained 11 thera-
peutic areas and 1 ‘other’ category.
From the trials included, we will extract data on the
stages of progress, non-publication and selective publica-
tion. In addition to the public data sources and original
trial protocols, we plan to send out a questionnaire to
the investigators. An overview of the variables we plan to
extract is presented in the data extraction form (see
online supplementary table S2).
Stages of progress
For the 622 trials in the inception cohort, we will deter-
mine the various stages of progress (figure 1). For each
clinical drug trial, we will discriminate 10 stages of pro-
gress. Of these, five are intermediate (meaning that
further action is observed or possible), and five are def-
inite (meaning that no further action is observed or pos-
sible). We named the stages of progress according to the
flow of the cohort, shown in figure 1. The intermediate
stages of progress are: B1 approved by IRB; C1 started
inclusion; D1 completed as planned; D2 terminated
early; E1 published as article. The definite stages of pro-
gress are: B2 rejected by IRB; C2 Never started inclusion;
E2 Not published as article; F1 completely reported;
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F2 selectively reported. We primarily aim to investigate
the publication-related stages of progress E1, E2, F1 and
F2. However, to understand why these stages of progress
are not reached, we also determine the other stages of
progress. The stage of progress F2 (selectively reported)
is definite for the end of our data collection; later publi-
cations can still fill the remaining gaps by moving trials
to F1 (completely reported).
Non-publication
We search for publications on the trial results in the
scientific literature using a standardised algorithm
(figure 2). A publication is defined as a peer-reviewed
article containing at least methods and results. All
reports not fulfilling this publication (eg, results
reported in registries, conference abstracts containing
results, trial summaries on sponsor websites containing
methods and results) will be also collected. Peer-
reviewed publication is in our opinion the golden stand-
ard for reporting clinical research, but trial results can
be reported by other means (eg, registries, sponsor web-
sites, conference abstracts). Using only peer-reviewed
articles as end point for non-publication is in line with
the majority of other research.47 If we identify more
than one publication of trial results, we classify the publi-
cation as either primary (ie, containing the overall
results and conclusions) or secondary (ie, interim, post
hoc, subgroup or other analysis). In general, we assume
that this will be clearly stated in the publications.42
Other information collected includes the full-text of the
article, the journal and the first date of publication (eg,
advance online publication). We have completed this
part of the publication search in March 2015.
We will also collect the end of trial date and informa-
tion about (early) termination of the trial. We define
the end of trial date as the date of the last visit of the
last patient undergoing the trial.50 A trial is terminated
early if either the inclusion or the follow-up is termi-
nated earlier than foreseen in the research protocol.
Since early termination is an intermediate stage of pro-
gress of a trial, we include early termination as a poten-
tial determinant for the end points studied. In addition,
prospective registration on clinicaltrials.gov will be exam-
ined as a potential determinant (table 1). We define
prospective registration as registration of the trial before
the first patient is recruited.1 The data field ‘first
received’ on clinicaltrials.gov will be used as the date of
registration.
To validate the used publication search algorithm, two
investigators independently searched for publications
using the algorithm, using a random selection of 30 trials
of the cohort. The two searches identified no differences.
Figure 1 Overview of stages of progress of the 2007 inception cohort of clinical drug trials in the Netherlands. The numbers in
the boxes indicate the numbers of trials that succeeded to the specific stages of progress. From B1, C1, D1, E1 to F1 is the
‘perfect’ flow of a trial in the cohort, meaning that all aspects took place according to the application. The sum of the boxes B2,
C2, E2 F1 and F2, which are the five final stages of progress, will be 622.
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We checked the external validity of the algorithm by com-
paring the results to a search algorithm used for another
study,33 provided by the investigators. This comparison
showed no differences, which suggested that the construct
validity of our algorithm was adequate.
In addition, we will send questionnaires to the main
investigators of the research divisions or hospital depart-
ments that conducted the trials. We will specifically ask
the investigators to confirm or rectify our information
about which stage of progress the trial reached accord-
ing to our findings. For the non-published trials, we ask
for the reasons that the trial was not published (box 1)
and whether the results of the trial were reported in
alternative ways, such as on clinicaltrials.gov. When the
investigator does not respond to the mailed
questionnaire, we will try to engage the investigator by
telephone contact. In case we are unable to contact the
investigator, we will contact the sponsor of the trial.
The various stages of progress of the trial in the flow-
chart will be updated according to the results of the
questionnaire. In case neither the investigator nor the
sponsor could be reached, the stages of progress remain
unchanged. We assume that if a trial was incorrectly
placed in the stage of progress boxes C2, D2, or E2, the
investigator or sponsor would have responded. If we are
unable to find any information on whether a trial
started inclusion, ended or was published, we will
exclude the trial for subsequent analysis. After showing
construct validity, the publication search was performed
by two authors (CAvdB and MvH), double-checked by
Figure 2 Publication search algorithm. EudraCT, European Union Drug Regulating Authorities Clinical Trials: obligatory
registration database for clinical drug trials carried out in the European Union.













Discrepancies between protocol and publication* Direction of publication
conclusions‡
*Only among randomised trials.
†Only among published trials.
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the questionnaire to the investigators. To assess the likeli-
hood of bias, we will investigate whether the character-
istics of included cases differ from excluded cases.
Selective publication
Among the trial protocols that resulted in a publication,
we will further investigate selective publication. We
include only peer-reviewed articles for the discrepancy
analysis because other reports contain too little detail to
investigate discrepancies with the trial protocol. Selective
publication can be measured by identifying discrepan-
cies between protocol and publication. Discrepancies
between protocol and publication are indications of
selective publication, which may lead to reporting bias.
The degree of the risk of reporting bias depends on the
association of discrepancies with the direction of trial
conclusions. Therefore, among the trials with a rando-
mised design, we will also assess the direction of publica-
tion conclusions and investigate whether the direction
of publication conclusions is associated with discrepan-
cies between protocol and publication.
We define discrepancies between protocol and
primary publication as additions, omissions or changes
in prespecified discrepancy-items. To identify discrepan-
cies systematically, we developed an extraction form con-
taining relevant items. We used items from common
protocol and publication guidelines like SPIRIT and
CONSORT to compel a list with trial items that should
be reported. From that list, we selected seven items in
which we expected selective reporting (see online sup-
plementary table S2).33 36 37 The seven discrepancy
items include: (1) objectives, (2) inclusion and exclusion
criteria, (3) end points, (4) sample size, (5) additional
analyses, (6) type of population analysis and (7) sponsor
acknowledgement. We will extract these items both from
the protocols and the publications. Subsequently, we will
compare the extracted data of the protocol to the publi-
cations. With regard to discrepancies in the objectives
and end points, we will distinguish between discrepan-
cies in the primary and in the secondary objectives, and
end points. With regard to discrepancies in the inclusion
and exclusion criteria, we will only consider an objective
change as discrepancy because inclusion and exclusion
criteria are often not fully reported in publications due
to the limited availability of space. We will operationalise
discrepancies in the planned versus included sample
size as the ratio of sample size achieved divided by
sample size planned. With regard to discrepancies in the
type of population analysis, we will assess whether an
intention-to-treat or per-protocol analysis was planned
and used accordingly. We will also indicate when there
was a lack of information in the protocol and/or in the
publication to assess a discrepancy.
In case we identify multiple publications of one trial
protocol, we will include the primary publication in the
discrepancy assessment. In addition, if a secondary pub-
lication contains any analyses that were not described in
the study protocol and this was not stated in the publica-
tion, we classify that as an additional discrepancy.
The discrepancy assessment was developed by one
author (CAvdB), and will be tested for construct validity
by a second author (PCS) by performing an independent
discrepancy assessment of a random selection of 10% of
the published trials. Remaining differences will be solved
by discussing these with two other authors (CTMB and
SWJJ). The remaining trials will then be assessed by one
author (CAvdB), with a randomly selected double-check
of 20 of the published trials by a second author (PCS).
Uncertainties will be solved by a discussion involving two
other authors (CTMB and SWJJ).
Among the trials with a randomised design, we will
classify the direction of publication conclusions as either
positive or negative. This classification is included to
investigate whether discrepancies are associated with the
direction of the conclusions (and the interpretation) that
the authors draw in the discussion sections of the publica-
tions. If trials with a positive conclusion have more dis-
crepancies than trials with a negative conclusion, this may
mean that discrepancies are used to spin trial conclusions
towards a positive direction. Two independent investiga-
tors (CAvdB and PCS) will independently classify the
trials, and solve differences by consensus.
Data analysis
According to the objectives of the study, we will analyse
three end points (table 1): non-publication, discrepan-
cies between the protocol and the publication as a proxy
for selective publication and the direction of publication
conclusions.
Non-publication
In a survival analysis of the non-publication rate, only
trials that started inclusion will be analysed (box C1 of
figure 1). The end point used is non-publication as peer-
reviewed article, according to the definition provided
above. The trial end date marks the start of follow-up
(ie, the date the trial transits to the stage of progress D1
or D2, figure 1). We chose this date instead of the date
of IRB approval because the trials in the cohort might
differ in time span. This time span may depend, for
example, on the phase of the trial and the number of
participants to be recruited. In case of multiple publica-
tions of one trial protocol, we use the publication date
of the primary publication.
We assume that all trials that started including patients
are eligible for publication. Thus, the population of the
Box 1 Reasons for not publishing results, to be obtained
from the questionnaire (for unpublished completed trials in
cohort)
▸ Manuscript is in preparation/under review
▸ Results were not interesting enough to publish
▸ Journal rejected the manuscript
▸ Sponsor decided not to publish without providing a reason
▸ Other
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non-publication survival analysis includes all trials that
started inclusion (box C1, figure 1). Trials that never
started inclusion are excluded from this analysis.
To identify characteristics that are associated with
(non-)publication, we perform Cox regression analysis
to estimate the strength of the association between
characteristics and publication status, expressed as HRs
and 95% CIs. Since trials of oncolytic drugs are different
with respect to the disease severity compared to most
trials in other therapeutic areas (which may affect publi-
cation), a stratified analysis will be conducted as well. In
addition, we will tabulate reasons for non-publication.
Finally, we will describe the means of publication by
other means than by the definition of publication. By
doing so, we will identify the subset of trials with no
results reported at all (not as peer-reviewed article and
not by any other means).
Selective publication
For each of the seven discrepancy-items, we calculate the
proportion of trials with the discrepancy. We investigate the
association between characteristics and discrepancies for
each item (χ2 test) and for the total discrepancy summary
score (paired t test). We will use multivariate logistic (indi-
vidual discrepancies) and linear (total discrepancy score)
regression models to estimate the strength of the associ-
ation of characteristics and publication status, expressed as
ORs and 95% CIs. Among the trials with a randomised
design, we investigate whether the discrepancies are asso-
ciated with the direction of the publication conclusions
using identical bivariate and multivariate analyses. Data ana-
lysis will be performed by two authors (CAvdB and PCS),
and double-checked by all other authors.
By measuring non-publication and selective publica-
tion, the study will identify the extent of research under-
reporting waste in a cohort of clinical trials in the
Netherlands.51 52 To increase the value derived from
clinical trials, transparency from protocol to the public
is needed.53 Our study will provide this on a national
level and may elucidate areas for improvement.
Ultimately, this study may contribute to evidence-based
medicine by improving the unbiased reporting rates of
clinical drug trials. This may increase the overall trust in
research on drugs and the willingness of participants to
enrol in clinical drug trials.
ETHICS AND DISSEMINATION
As our study involves no human participants, no
IRB-approval is required. Access to confidential research
protocols was provided by the Central Committee on
Research Involving Human Subjects. We plan to finish
data collection in June 2015, and expect to complete
data cleaning, analysis and manuscript preparation
within the next 3 months. Hence, a first draft of an
article containing the results is expected before the end
of October 2015.
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